This study aims to see if using TAR-200 with a medicine called cetrelimab helps people with muscle-invasive bladder cancer live longer without needing bladder removal, compared to regular treatment like chemotherapy (using strong medicines) and radiation (using high-energy rays). TAR-200 is a small, flexible device placed in the bladder to release medicine directly. Cetrelimab is given through an IV, which means it's put directly into a vein. Participants should be in good health, as shown by tests like blood and liver checks. They should not have cancer outside the bladder or too many cancer spots in the bladder. The study doesn't need bladder surgery, but there are some risks, like possible difficulty placing the TAR-200 device.

• The study requires regular check-ups and tests for safety and effectiveness.
• Participants must not be eligible or choose not to have bladder removal surgery.
• Compensation may be provided for time and travel costs.